Rising Amid Flurry of CAR T Deals, Stylus Proves Cell Therapy Is Not Dead

from BioSpace · host BioSpace

Stylus Medicine CEO Emile Nuwaysir and Chief Scientific Officer Jason Fontenot speak with BioSpace about the biotech's work on next-generation genetic medicines—and why they think it’s the perfect time to be in the cell therapy game. Stylus Medicine is featured in BioSpace's list, the top startups to watch in the U.S.HostAnnalee Armstrong, Senior Editor, BioSpaceGuestsEmile Nuwaysir, CEO, Stylus MedicineJason Fontenot, Chief Scientific Officer, Stylus MedicineDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Episode metadata supplied by the publisher feed · Published Mar 10, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Rising Amid Flurry of CAR T Deals, Stylus Proves Cell Therapy Is Not Dead

0:00 21:18

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioSpace?

This episode is 21 minutes long.

When was this BioSpace episode published?

This episode was published on March 10, 2026.

Can I download this BioSpace episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!